Truist lowered the firm’s price target on Regeneron (REGN) to $812 from $940 and keeps a Buy rating on the shares. The near-term investor focus remains on the Eylea tail and Eylea HD uptake, though Regeneron continues to deliver growth on its top and bottom line with Dupi and Libtayo programs, the analyst tells investors in a research note. Truist adds that it sees near-term value inflection points with additional launches and label expansions, along with a robust and maturing pipeline.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Asthma Treatment
- Regeneron and Sanofi’s Dupilumab Trial: A Potential Game-Changer for Ulcerative Colitis
- Regeneron’s Promising Phase 3 Melanoma Study: A Potential Game-Changer?
- Regeneron’s Phase 3 Study on Odronextamab: A Potential Game-Changer for B-cell Lymphoma
- Regeneron’s Promising Immunotherapy Study for Advanced Lung Cancer